Latest Healthcare News

Epsilon Healthcare Limited reported a $3.25 million loss for 2024, reflecting the financial strain of voluntary administration and efforts to rebuild operations and client confidence.

Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.

Echo IQ’s application for a Category III CPT code was declined by the AMA, but the company is exploring reconsideration and new AI-specific coding frameworks to advance US reimbursement.

Artrya Limited has successfully completed a strongly supported Share Purchase Plan, raising approximately A$5 million despite significant oversubscription. This follows a recent $75 million placement, underscoring investor confidence in its AI-driven coronary artery disease platform.

Unith Ltd reported an 18.8% increase in FY 2025 revenue to A$5.37 million alongside a significant capital raise, positioning itself for expansion in the burgeoning AI Digital Humans market.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Micro-X has landed a $3.3 million order from the Malaysian Ministry of Health for its Rover Plus mobile X-ray units, marking a significant step in its Southeast Asian expansion. Delivery is set to begin in October 2025.

Pacific Smiles Group announces the resignation of CEO Gary Carroll and the appointment of Michelle Dries as his successor, signaling a new chapter for the dental services provider.

Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.

Australian Unity Limited has opened a $101 million non-renounceable entitlement offer alongside a $160 million placement, aiming to strengthen its balance sheet and support ongoing acquisitions. The company also announced the appointment of Kelly Bayer Rosmarin as its next CEO, signaling a new chapter in leadership.

Orthocell has reported a record $3 million revenue for the September quarter, driven by strong sales of its nerve repair product Remplir™ in Australia and Singapore, with early US sales and Canadian market entry poised to accelerate growth.

ImpediMed secures expanded insurance reimbursement for its SOZO platform, now covering over 301 million US lives and enhancing early detection of breast cancer-related lymphedema.